Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013 (2013), Article ID 523170, 8 pages
http://dx.doi.org/10.1155/2013/523170
Review Article

Helicobacter pylori Infection, Chronic Inflammation, and Genomic Transformations in Gastric MALT Lymphoma

Department of Experimental Hematology, Medical University of Lodz, Ciolkowskiego 2, 93-510 Lodz , Poland

Received 4 January 2013; Accepted 11 February 2013

Academic Editor: David Bernardo Ordiz

Copyright © 2013 Magdalena Witkowska and Piotr Smolewski. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Isaacson and M. Du, “MALT lymphoma: from morphology to molecules,” Nature Reviews, vol. 52, no. 4, pp. 644–653, 2004. View at Google Scholar
  2. S. H. Swerdlow, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, Lyon, France, 4th edition, 2007.
  3. D. M. Weber, M. A. Dimopoulos, D. P. Anandu, W. C. Pugh, and G. Steinbach, “Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for Helicobacter pylori,” Gastroenterology, vol. 107, no. 6, pp. 1835–1838, 1994. View at Google Scholar · View at Scopus
  4. B. J. Marshall and J. R. Warren, “Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration,” The Lancet, vol. 1, no. 8390, pp. 1311–1314, 1984. View at Google Scholar · View at Scopus
  5. N. Uemura, S. Okamoto, S. Yamamoto et al., “Helicobacter pylori infection and the development of gastric cancer,” The New England Journal of Medicine, vol. 345, no. 11, pp. 784–789, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Morgner, E. Bayerdörffer, A. Neubauer, and M. Stolte, “Malignant tumors of the stomach: gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori,” Gastroenterology Clinics of North America, vol. 29, no. 3, pp. 593–607, 2000. View at Google Scholar · View at Scopus
  7. P. M. Banks, “Gastrointestinal lymphoproliferative disorders,” Histopathology, vol. 50, no. 1, pp. 42–54, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. J. L. O'Rourke, “Gene expression profiling in Helicobacter-induced MALT lymphoma with reference to antigen drive and protective immunization,” Journal of Gastroenterology and Hepatology, vol. 23, no. 2, pp. S151–S156, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Munari, S. Lonardi, M. A. Cassatella et al., “Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma,” Blood, vol. 117, no. 24, pp. 6612–6616, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Suarez, O. Lortholary, O. Hermine, and M. Lecuit, “Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation,” Blood, vol. 107, no. 8, pp. 3034–3044, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Royer, D. Cazals-Hatem, J. Sibilia et al., “Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses,” Blood, vol. 90, no. 2, pp. 766–775, 1997. View at Google Scholar · View at Scopus
  12. G. A. Derringer, L. D. R. Thompson, R. A. Frommelt, K. E. Bijwaard, C. S. Heffess, and S. L. Abbondanzo, “Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases,” The American Journal of Surgical Pathology, vol. 24, no. 5, pp. 623–639, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. E. G. Levine, D. C. Arthur, J. Machnicki et al., “Four new recurring translocations in non-Hodgkin lymphoma,” Blood, vol. 74, no. 5, pp. 1796–1800, 1989. View at Google Scholar · View at Scopus
  14. P. Starostik, J. Patzner, A. Greiner et al., “Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways,” Blood, vol. 99, no. 1, pp. 3–9, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. H. Liu, A. Ruskon-Fourmestraux, A. Lavergne-Slove et al., “Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy,” The Lancet, vol. 357, no. 9249, pp. 39–40, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Streubel, I. Simonitsch-Klupp, L. Müllauer et al., “Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites,” Leukemia, vol. 18, no. 10, pp. 1722–1726, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Ye, L. Gong, H. Liu et al., “MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 expression,” The Journal of Pathology, vol. 205, no. 3, pp. 293–301, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. E. D. Remstein, A. Dogan, R. R. Einerson et al., “The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America,” The American Journal of Surgical Pathology, vol. 30, no. 12, pp. 1546–1553, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Ruland, G. S. Duncan, A. Elia et al., “Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure,” Cell, vol. 104, no. 1, pp. 33–42, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Xue, S. W. Morris, C. Orihuela et al., “Defective developmental and function of Bcl10-deficient follicular, marginal zone and B1 B cells,” Nature Immunology, vol. 4, no. 9, pp. 857–865, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Libra, V. De Re, A. Gloghini et al., “Detection of bcl-2 rearrangement in mucosa-associated lymphoid tissue lymphomas from patients with hepatitis C virus infection,” Haematologica, vol. 89, no. 7, pp. 873–874, 2004. View at Google Scholar · View at Scopus
  22. B. Streubel, U. Vinatzer, A. Lamprecht, M. Raderer, and A. Chott, “T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma,” Leukemia, vol. 19, no. 4, pp. 652–658, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. E. D. Remstein, A. Dogan, R. R. Einerson et al., “The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America,” The American Journal of Surgical Pathology, vol. 30, no. 12, pp. 1546–1553, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Haralambieva, P. Adam, R. Ventura et al., “Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation,” Leukemia, vol. 20, no. 7, pp. 1300–1303, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Sagaert, P. De Paepe, L. Libbrecht et al., “Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma,” Journal of Clinical Oncology, vol. 24, no. 16, pp. 2490–2497, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Thome, “CARMA1, BCL-10 and MALT1 in lymphocyte development and activation,” Nature Reviews Immunology, vol. 4, no. 5, pp. 348–359, 2004. View at Google Scholar · View at Scopus
  27. X. Lin and D. Wang, “The roles of CARMA1, Bcl10, and MALT1 in antigen receptor signaling,” Seminars in Immunology, vol. 16, no. 6, pp. 429–435, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Y. Pei, S. H. Kuo, K. H. Yeh et al., “A pathway for tumor necrosis factor-α-induced Bcl10 nuclear translocation: Bcl10 is up-regulated by NF-κB and phosphorylated by Akt1 and then complexes with Bcl3 to enter the nucleus,” The Journal of Biological Chemistry, vol. 281, no. 1, pp. 167–175, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Batten, C. Fletcher, L. G. Ng et al., “TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma,” Journal of Immunology, vol. 172, no. 2, pp. 812–822, 2004. View at Google Scholar · View at Scopus
  30. A. J. Novak, D. M. Grote, M. Stenson et al., “Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome,” Blood, vol. 104, no. 8, pp. 2247–2253, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. J. E. Everhart, D. Kruszon-Moran, and G. Perez-Perez, “Reliability of Helicobacter pylori and CagA serological assays,” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 2, pp. 412–416, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. J. G. Fox, “The non-H pylori helicobacters: their expanding role in gastrointestinal and systemic diseases,” Gut, vol. 50, no. 2, pp. 273–283, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Zucca and M. Dreyling, “Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 21, supplement 5, pp. v175–v176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Musshoff and H. Schmidt Vollmer, “Prognosis of non Hodgkin's lymphomas with special emphasis on the staging classification,” Zeitschrift fur Krebsforschung und Klinische Onkologie, vol. 83, no. 4, pp. 323–341, 1975. View at Google Scholar · View at Scopus
  35. A. Zullo, C. Hassan, F. Cristofari et al., “Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma,” Clinical Gastroenterology and Hepatology, vol. 8, no. 2, pp. 105–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Caselli, A. Zullo, G. Maconi et al., “‘Cervia II Working Group Report 2006’: guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy,” Digestive and Liver Disease, vol. 39, no. 8, pp. 782–789, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Malfertheiner, F. Megraud, C. O. 'Morain et al., “Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report,” Gut, vol. 56, no. 6, pp. 772–781, 2007. View at Google Scholar
  38. K. M. Fock, P. Katelaris, K. Sugano et al., “Second Asia-Pacific consensus guidelines for Helicobacter pylori infection,” Journal of Gastroenterology and Hepatology, vol. 24, no. 10, pp. 1587–1600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Zullo, C. Hassan, A. Andriani et al., “Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis,” The American Journal of Gastroenterology, vol. 104, no. 8, pp. 1932–1937, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Koch, F. Del Valle, W. E. Berdel et al., “Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma—results of the prospective German multicenter study GIT NHL 01/92,” Journal of Clinical Oncology, vol. 19, no. 18, pp. 3874–3883, 2001. View at Google Scholar · View at Scopus
  41. D. L. Bartlett, M. S. Karpeh Jr., D. A. Filippa, and M. F. Brennan, “Long-term follow-up after curative surgery for early gastric lymphoma,” Annals of Surgery, vol. 223, no. 1, pp. 53–62, 1996. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Yahalom, “MALT lymphomas: a radiation oncology viewpoint,” Annals of Hematology, vol. 80, supplement 3, pp. B100–B105, 2001. View at Google Scholar
  43. P. Koch, A. Probst, W. E. Berdel et al., “Treatment results in localized primary gastric lymphoma: data of patients registered within the German Multicenter study (GIT NHL 02/96),” Journal of Clinical Oncology, vol. 23, no. 28, pp. 7050–7059, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. S. S. Yoon, D. G. Coit, C. S. Portlock, and M. S. Karpeh, “The diminishing role of surgery in the treatment of gastric lymphoma,” Annals of Surgery, vol. 240, no. 1, pp. 28–37, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Nakamura, T. Matsumoto, H. Suekane et al., “Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment,” Cancer, vol. 104, no. 3, pp. 532–540, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. P. L. Zinzani, V. Stefoni, G. Musuraca et al., “Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma,” Cancer, vol. 100, no. 10, pp. 2190–2194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Jäger, P. Neumeister, R. Brezinschek et al., “Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a Phase II study,” Journal of Clinical Oncology, vol. 20, no. 18, pp. 3872–3877, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. B. Streubel, H. Ye, M. Q. Du, P. G. Isaacson, A. Chott, and M. Raderer, “Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma,” Oncology, vol. 66, no. 6, pp. 476–480, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Raderer, S. Wohrer, R. Bartsch et al., “Phase II Study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma,” Journal of Clinical Oncology, vol. 23, no. 33, pp. 8442–8446, 2005. View at Publisher · View at Google Scholar
  50. G. Jäger, P. Neumeister, F. Quehenberger, S. Wöhrer, W. Linkesch, and M. Raderer, “Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial,” Annals of Oncology, vol. 17, no. 11, pp. 1722–1723, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Martinelli, D. Laszlo, A. J. M. Ferreri et al., “Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 1979–1983, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Conconi, G. Martinelli, A. Lopez-Guillermo et al., “Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG),” Annals of Oncology, vol. 22, no. 3, pp. 689–695, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. M. Raderer, S. Wöhrer, B. Streubel et al., “Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma,” Oncology, vol. 70, no. 6, pp. 411–417, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Troch, B. Kiesewetter, W. Willenbacher et al., “Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphomaof the mucosa associated lymphoid tissue-Lymphoma: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie,” Haematologica, vol. 98, no. 2, pp. 264–268, 2013. View at Publisher · View at Google Scholar
  55. B. Kiesewetter, M. Troch, W. Dolak et al., “A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma),” Haematologica. In press. View at Google Scholar
  56. P. McLaughlin, A. J. Grillo-López, B. K. Link et al., “Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2825–2833, 1998. View at Google Scholar · View at Scopus
  57. A. Conconi, G. Martinelli, C. Thiéblemont et al., “Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type,” Blood, vol. 102, no. 8, pp. 2741–2745, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. N. Chaudhary, H. Ozer, D. Huard, S. Lightfoot, and S. Mesiya, “Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab,” Digestive Diseases and Sciences, vol. 51, no. 4, pp. 775–778, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Salar, B. Bellosillo, S. Serrano, and C. Besses, “Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab,” Journal of Clinical Oncology, vol. 23, no. 29, pp. 7361–7362, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. E. Zucca, A. Conconi, G. Martinelli et al., “Chlorambucil plus rituximab produces better eventfree survival in comparison with chlorambucil alone in the treatment of MALT lymphoma: 5-year analysis of the 2-arms part of the IELSG-19 randomized study,” Blood, vol. 116, p. 432, 2010, (ASH Annual Meeting Abstracts). View at Google Scholar
  61. A. Zullo, C. Hassan, A. Andriani et al., “Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis,” The American Journal of Gastroenterology, vol. 104, no. 8, pp. 1932–1937, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Andriani, A. Miedico, L. Tedeschi et al., “Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, Multicentre study,” Digestive and Liver Disease, vol. 41, no. 7, pp. 467–473, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. L. G. Capelle, A. C. de Vries, C. W. N. Looman et al., “Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study,” European Journal of Cancer, vol. 44, no. 16, pp. 2470–2476, 2008. View at Publisher · View at Google Scholar · View at Scopus